ACTUALIZACIÓN:
暂无分享,去创建一个
[1] N. Papadopoulos,et al. Face masks, respiratory patients and COVID-19 , 2020, European Respiratory Journal.
[2] M. Miravitlles,et al. GesEPOC 2021: One More Step Towards Personalized Treatment of COPD. , 2020, Archivos de bronconeumologia.
[3] F. Martín-Sánchez,et al. Management and follow up of respiratory patients in the post-Covid-19 era: Are we ready yet? , 2020, Archivos de Bronconeumología (English Edition).
[4] M. Miravitlles,et al. A Proposed Approach to Chronic Airway Disease (CAD) Using Therapeutic Goals and Treatable Traits: A Look to the Future , 2020, International journal of chronic obstructive pulmonary disease.
[5] M. Miravitlles,et al. The Importance of Reference Centers and Registries for Rare Diseases: The Example of Alpha-1 Antitrypsin Deficiency , 2020, COPD.
[6] D. Price,et al. Changes in Control Status of COPD Over Time and Their Consequences: A Prospective International Study. , 2020, Archivos de bronconeumologia.
[7] P. Dorinsky,et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. , 2020, The New England journal of medicine.
[8] M. Martínez-García,et al. Consensus Document on the Diagnosis and Treatment of Chronic Bronchial Infection in Chronic Obstructive Pulmonary Disease. , 2020, Archivos de bronconeumologia.
[9] M. Miravitlles,et al. Current Challenges in Chronic Bronchial Infection in Patients with Chronic Obstructive Pulmonary Disease , 2020, Journal of clinical medicine.
[10] M. Miravitlles,et al. The right treatment for the right patient with COPD: lessons from the IMPACT trial , 2020, European Respiratory Journal.
[11] J. Wedzicha,et al. Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline , 2020, American journal of respiratory and critical care medicine.
[12] D. Price,et al. Predictive value of control of COPD for risk of exacerbations: An international, prospective study , 2020, Respirology.
[13] A. Aldhahir,et al. Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis , 2020, medRxiv.
[14] G. Lippi,et al. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19) , 2020, Respiratory Medicine.
[15] J. Curtis,et al. Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease , 2020, American journal of respiratory and critical care medicine.
[16] M. Miravitlles,et al. Spanish Implementation of the New International Alpha-1 Anitrypsin Deficiency International Registry: The European Alpha-1 Research Collaboration (EARCO). , 2020, Archivos de bronconeumologia.
[17] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[18] M. Miravitlles,et al. Blood Eosinophil Counts and Their Variability and Risk of Exacerbations in COPD: A Population-Based Study. , 2020, Archivos de bronconeumologia.
[19] M. Miravitlles,et al. Clinical Control in COPD: A New Therapeutic Objective? , 2020, Archivos de Bronconeumologia.
[20] J. López-Campos,et al. The Clinical Implications of Triple Therapy in Fixed-Dose Combination in COPD: From the Trial to the Patient. , 2020, Archivos de bronconeumologia.
[21] M. Miravitlles,et al. Clinical Characteristics and Risk of Exacerbations Associated With Different Diagnostic Criteria of Asthma-COPD Overlap. , 2019 .
[22] J. Soriano,et al. Adjusting the Level of Intervention in Patients with Chronic Obstructive Pulmonary Disease According to the Risk Stratification Proposed by the Spanish COPD Guidelines (GesEPOC) Version 2017. , 2019 .
[23] R. Golpe,et al. Plasma Eosinophil Count and Patient-Centered Events in Chronic Obstructive Pulmonary Disease in Real-Life Clinical Practice. , 2019 .
[24] E. Kerwin,et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial , 2019, Respiratory Research.
[25] Meilan K. Han,et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. , 2019, The Lancet. Respiratory medicine.
[26] B. Celli,et al. Prognostic Validation Using GesEPOC 2017 Severity Criteria. , 2019, Archivos de bronconeumologia.
[27] N. Zhong,et al. Tiotropium discontinuation in patients with early-stage COPD: a prospective observational cohort study , 2019, ERJ Open Research.
[28] J. Soriano,et al. ACO: Time to move from the description of different phenotypes to the treatable traits , 2019, PloS one.
[29] R. Golpe,et al. Should Lung Function Be Included in the Risk Stratification of Chronic Obstructive Pulmonary Disease Proposed by GesEPOC? , 2019, Archivos de bronconeumologia.
[30] F. Martinez,et al. Pulmonary hypertension in chronic lung disease and hypoxia , 2019, European Respiratory Journal.
[31] M. Miravitlles,et al. Recommendations on non-Pharmacological Treatment in Chronic Obstructive Pulmonary Disease From the Spanish COPD Guidelines (GesEPOC 2017). , 2018, Archivos de bronconeumologia.
[32] M. Miravitlles,et al. Validation of clinical control in COPD as a new tool for optimizing treatment , 2018, International journal of chronic obstructive pulmonary disease.
[33] S. Suissa,et al. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. , 2018, The Lancet. Respiratory medicine.
[34] F. Venuta,et al. Bronchoscopic treatment of emphysema: an update. , 2018, Journal of thoracic disease.
[35] A. Morice,et al. Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial , 2018, JAMA.
[36] M. Humbert,et al. Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype? , 2018, American journal of respiratory and critical care medicine.
[37] A. Anzueto,et al. The Role of Fixed-Dose Dual Bronchodilator Therapy in Treating COPD. , 2018, The American journal of medicine.
[38] C. Montón,et al. Clinical and Safety Outcomes of Long‐Term Azithromycin Therapy in Severe COPD Beyond the First Year of Treatment , 2018, Chest.
[39] J. Wedzicha,et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. , 2018, The Lancet. Respiratory medicine.
[40] Meilan K. Han,et al. Once‐Daily Single‐Inhaler Triple versus Dual Therapy in Patients with COPD , 2018, The New England journal of medicine.
[41] J. Barberà,et al. Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Summary of Recommendations. , 2018 .
[42] M. Miravitlles,et al. Accuracy of a New Algorithm to Identify Asthma-COPD Overlap (ACO) Patients in a Cohort of Patients with Chronic Obstructive Airway Disease. , 2017, Archivos de bronconeumologia.
[43] J. Soriano,et al. Asthma-COPD overlap is not a homogeneous disorder: further supporting data , 2017, Respiratory Research.
[44] J. Soriano,et al. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD , 2017, European Respiratory Journal.
[45] J. Soriano,et al. Spanish COPD Guidelines (GesEPOC) 2017. Pharmacological Treatment of Stable Chronic Obstructive Pulmonary Disease , 2017 .
[46] M. Miravitlles,et al. Bronchiectasis in COPD patients: more than a comorbidity? , 2017, International journal of chronic obstructive pulmonary disease.
[47] J. Soriano,et al. Clinical audit of COPD in outpatient respiratory clinics in Spain: the EPOCONSUL study , 2017, International journal of chronic obstructive pulmonary disease.
[48] Dave Singh,et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial , 2016, The Lancet.
[49] I. Pavord,et al. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. , 2016, The Lancet. Respiratory medicine.
[50] J. Curtis,et al. Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease. , 2016, Annals of the American Thoracic Society.
[51] R. Rodríguez-Roisín,et al. Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial. , 2016, Chest.
[52] M. Krstic,et al. Capsule endoscopy is useful diagnostic tool for diagnosing Meckel’s diverticulum , 2016, European journal of gastroenterology & hepatology.
[53] J. Wedzicha,et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. , 2016, The New England journal of medicine.
[54] M. Cazzola,et al. A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. , 2016, Chest.
[55] I. Pavord,et al. Treatable traits: toward precision medicine of chronic airway diseases , 2016, European Respiratory Journal.
[56] Berend C Stoel,et al. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.
[57] S. Johnston,et al. Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease. , 2014, The Lancet. Respiratory medicine.
[58] Jeffrey R Stout,et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS) , 2014, Age and ageing.
[59] Stefano Nava,et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. , 2014, The Lancet. Respiratory medicine.
[60] L. Raiteri,et al. Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD. , 2014, Chest.
[61] H. Hoogsteden,et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. , 2014, The Lancet. Respiratory medicine.
[62] L. Raiteri,et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. , 2014, The Lancet. Respiratory medicine.
[63] V. Plaza,et al. Calidad y fuerza: el sistema GRADE para la formulación de recomendaciones en las guías de práctica clínica , 2013 .
[64] J. Wedzicha,et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. , 2013, The Lancet. Respiratory medicine.
[65] M. Martínez-García,et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.
[66] B. Jiang,et al. Double-balloon enteroscopy for diagnosis of Meckel's diverticulum: comparison with operative findings and capsule endoscopy. , 2013, Surgery.
[67] P. Coppi,et al. Meckel’s scan in children: a review of 183 cases referred to two paediatric surgery specialist centres over 18 years , 2013, Pediatric Surgery International.
[68] A. Morice,et al. Azithromycin for prevention of exacerbations of COPD. , 2011 .
[69] W. Tom,et al. Omphalomesenteric Duct Remnants: Umbilical versus Umbilical Cord Lesions , 2011, Pediatric dermatology.
[70] Joan B Soriano,et al. Overdiagnosing subjects with COPD using the 0.7 fixed ratio: correlation with a poor health-related quality of life. , 2011, Chest.
[71] K. Rabe,et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. , 2011, The New England journal of medicine.
[72] D. D. Briggs,et al. Evaluation of withdrawal of maintenance tiotropium in COPD. , 2009, Respiratory medicine.
[73] Lucas M Bachmann,et al. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis , 2009, BMC Medicine.
[74] N. Zhong,et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study , 2008, The Lancet.
[75] J. E. Hansen,et al. Spirometric criteria for airway obstruction: Use percentage of FEV1/FVC ratio below the fifth percentile, not < 70%. , 2007, Chest.
[76] C. Snyder. Current management of umbilical abnormalities and related anomalies. , 2007, Seminars in pediatric surgery.
[77] F. Sutherland,et al. Complications of Meckel's diverticula in adults. , 2006, Canadian journal of surgery. Journal canadien de chirurgie.
[78] J. Sagar,et al. Meckel's Diverticulum: a Systematic Review , 2006, Journal of the Royal Society of Medicine.
[79] N. Zhong,et al. Positive benefits of theophylline in a randomized, double‐blind, parallel‐group, placebo‐controlled study of low‐dose, slow‐release theophylline in the treatment of COPD for 1 year , 2006, Respirology.
[80] A. Koch,et al. The Significance of Meckel’s Diverticulum in Appendicitis — A Retrospective Analysis of 233 Cases , 2005, World Journal of Surgery.
[81] John J. Park,et al. Meckel Diverticulum: The Mayo Clinic Experience With 1476 Patients (1950–2002) , 2005, Annals of surgery.
[82] P. Suhocki,et al. Gastrointestinal bleeding in adult patients with Meckel's diverticulum: the role of technetium 99m pertechnetate scan. , 2002, Southern medical journal.
[83] R. Zuwallack,et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. , 2001, Chest.
[84] Y. Maehara,et al. Complications and diagnosis of Meckel's diverticulum in 776 patients. , 1992, American journal of surgery.
[85] J. Escarrabill,et al. Ventilación mecánica a domicilio , 1990 .
[86] J. Corkery,et al. Meckel's diverticulum: Its association with congenital malformation and the significance of atypical morphology , 1980, The British journal of surgery.
[87] A. H. Bill,et al. The natural history of Meckel's Diverticulum and its relation to incidental removal. A study of 202 cases of diseased Meckel's Diverticulum found in King County, Washington, over a fifteen year period. , 1976, American journal of surgery.
[88] H. Buchsbaum. Meckel's Diverticulum , 1975, Obstetrics and gynecology.
[89] C. Olveira,et al. Spanish Guidelines on the Evaluation and Diagnosis of Bronchiectasis in Adults , 2017 .
[90] M. Miravitlles,et al. Consensus on the Asthma-COPD Overlap Syndrome (ACOS) Between the Spanish COPD Guidelines (GesEPOC) and the Spanish Guidelines on the Management of Asthma (GEMA). , 2017, Archivos de bronconeumologia.
[91] J. Soriano,et al. Defining the Asthma-COPD Overlap Syndrome in a COPD Cohort. , 2016, Chest.
[92] L. Puente Maestu,et al. Continuous home oxygen therapy. , 2014, Archivos de bronconeumologia.
[93] C. Cooper,et al. The role of long-acting bronchodilators in the management of stable COPD. , 2004, Chest.
[94] F. Ram,et al. Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. , 2000, The Cochrane database of systematic reviews.